Page results
-
This page provides information about the Palliative care and symptom control team
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
EMIS outage caused backlog of result messages via Keystone
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy). We provide multidisciplinary care for patients who are referred from their GP or from other hospitals. Although immune-related neurotoxicity is relatively rare it may be severe and is associated with significant disability and high risk to patients if not recognised and managed promptly and well.
-
A team of clinician scientists at UCLH have identified the factors which predict full hearing recovery, with the strongest predictor being treatment with steroids within seven days of a sudden drop in hearing.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
This information is to help you understand your forthcoming treatment and contains answers to many frequently asked questions. If you have any questions that this does not answer, or would like…
-
This page provides information for patients and carers about questionnaires.
-
We provide routine histopathological diagnoses using both standard techniques and advanced diagnostics including immunocytochemistry, fluoresent in-situ hybridisation (FISH), and polymerase chain…
